Seal Biosciences
We are developing diagnostic assays to identify patients who are most likely to respond to targeted cancer therapies. Our first assay for RasGRP1, has been clinically validated as a predictive and prognostic marker for response to anti-EGFR therapy in metastatic colorectal cancer. We are currently exploring other indications where inhibition of the EGFR pathway is a central therapeutic modality, and uncovering more about the role of RasGRP1 in regulation of this key signaling pathway.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1 to 10
headcount range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Seal Biosciences
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Seal Biosciences
1 distinct titles indexed · top 1 shown.
- 1project manager
Sign up to unlock all 1 contacts at Seal Biosciences
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Seal Biosciences
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.